JP2017505285A5 - - Google Patents

Download PDF

Info

Publication number
JP2017505285A5
JP2017505285A5 JP2016532631A JP2016532631A JP2017505285A5 JP 2017505285 A5 JP2017505285 A5 JP 2017505285A5 JP 2016532631 A JP2016532631 A JP 2016532631A JP 2016532631 A JP2016532631 A JP 2016532631A JP 2017505285 A5 JP2017505285 A5 JP 2017505285A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
agent according
salt
compound
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016532631A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505285A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/065742 external-priority patent/WO2015077154A1/en
Publication of JP2017505285A publication Critical patent/JP2017505285A/ja
Publication of JP2017505285A5 publication Critical patent/JP2017505285A5/ja
Withdrawn legal-status Critical Current

Links

JP2016532631A 2013-11-20 2014-11-14 ホモ接合性家族性高コレステロール血症の治療 Withdrawn JP2017505285A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201361906837P 2013-11-20 2013-11-20
US61/906,837 2013-11-20
US201461942438P 2014-02-20 2014-02-20
US61/942,438 2014-02-20
US201461942941P 2014-02-21 2014-02-21
US61/942,941 2014-02-21
US201461974816P 2014-04-03 2014-04-03
US201461974725P 2014-04-03 2014-04-03
US201461974785P 2014-04-03 2014-04-03
US61/974,816 2014-04-03
US61/974,725 2014-04-03
US61/974,785 2014-04-03
PCT/US2014/065742 WO2015077154A1 (en) 2013-11-20 2014-11-14 Treatment of homozygous familial hypercholesterolemia

Publications (2)

Publication Number Publication Date
JP2017505285A JP2017505285A (ja) 2017-02-16
JP2017505285A5 true JP2017505285A5 (enExample) 2017-12-21

Family

ID=52014370

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016532631A Withdrawn JP2017505285A (ja) 2013-11-20 2014-11-14 ホモ接合性家族性高コレステロール血症の治療

Country Status (14)

Country Link
US (1) US20150139987A1 (enExample)
EP (1) EP3071198A1 (enExample)
JP (1) JP2017505285A (enExample)
KR (1) KR20160079124A (enExample)
CN (1) CN105764498A (enExample)
AU (1) AU2014353246A1 (enExample)
CA (1) CA2930069A1 (enExample)
CL (1) CL2016001215A1 (enExample)
EA (1) EA201691039A1 (enExample)
HK (1) HK1224186A1 (enExample)
IL (1) IL245748A0 (enExample)
MX (1) MX2016006583A (enExample)
PH (1) PH12016500886A1 (enExample)
WO (1) WO2015077154A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
MX367076B (es) 2012-12-05 2019-08-05 Alnylam Pharmaceuticals Inc Composiciones de arni de proteina convertasa subtilisina kexina 9 (pcsk9) y metodos de uso de las mismas.
US9624172B2 (en) 2014-02-17 2017-04-18 Hetero Research Foundation Polymorphs of lomitapide and its salts
JP6568577B2 (ja) 2014-03-20 2019-08-28 サイマベイ・セラピューティクス・インコーポレイテッドCymaBay Therapeutics,Inc. 肝内胆汁うっ滞症の治療
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
PH12016501978B1 (en) 2014-04-11 2023-07-12 Cymabay Therapeutics Inc Treatment of nafld and nash
BR102015025502B1 (pt) * 2015-04-30 2022-06-21 Aegerion Pharmaceuticals, Inc Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição
CN118697894A (zh) * 2015-08-25 2024-09-27 阿尔尼拉姆医药品有限公司 用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物
CN105481758A (zh) * 2016-01-13 2016-04-13 天津药物研究院有限公司 一种洛美他派晶型ⅰ及其制备方法和用途
EA201891979A1 (ru) 2016-03-03 2019-01-31 Ридженерон Фармасьютикалз, Инк. Способы лечения пациентов с гиперлипидемией введением ингибитора pcsk9 в комбинации с ингибитором angptl3
HUE071912T2 (hu) * 2016-04-28 2025-10-28 Regeneron Pharma Eljárások örökletes hiperkoleszterinémiában szenvendõ betegek kezelésére
WO2017200715A1 (en) * 2016-05-19 2017-11-23 Cymabay Therapeutics, Inc. Treatment of severe hyperlipidemia
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CN111836620B (zh) * 2017-11-23 2023-11-03 浙江海正药业股份有限公司 一种海泽麦布和HMG-CoA还原酶抑制剂的药物组合物
JP2022518354A (ja) * 2018-12-20 2022-03-15 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 家族性高コレステロール血症を治療するための遺伝子療法
CN119119023A (zh) 2019-01-18 2024-12-13 阿斯利康(瑞典)有限公司 Pcsk9抑制剂及其使用方法
US20210145775A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of intestinal barrier dysfunction and associated diseases
US20210145774A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of alcoholic liver disease
JP2023536855A (ja) 2020-07-29 2023-08-30 アムリット・ファーマシューティカルズ・インコーポレイテッド 小児患者における高脂血症及び高コレステロール血症の治療方法における使用のためのロミタピド

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7301050B2 (en) 2003-09-19 2007-11-27 Janssen Pharmaceutical N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
HRP20130115T4 (hr) 2004-03-05 2016-04-22 The Trustees Of The University Of Pennsylvania Postupci liječenja poremećaja ili bolesti povezanih sa hiperlipidemijom i hiperkolesterolemijom uz minimizaciju sporednih efekata
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
KR20110091680A (ko) 2008-10-17 2011-08-12 메타볼렉스, 인코포레이티드 작고 조밀한 ldl 입자를 감소시키는 방법
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول

Similar Documents

Publication Publication Date Title
JP2017505285A5 (enExample)
JP2017513836A5 (enExample)
HRP20192299T1 (hr) Liječenje nafld i nash
HK1224186A1 (zh) 纯阖家族型高胆固醇血症的治疗
JP2017508817A5 (enExample)
JP2016513717A5 (enExample)
CY1119575T1 (el) Ενωσεις υποκατεστημενης βενζαλδεϋδης και μεθοδοι για τη χρηση τους στην αυξηση της οξυγονωσης του ιστου
CY1120939T1 (el) Συνδυασμος ρεγοραφενιμπης και ακετυλοσαλικυλικου οξεος για τη θεραπευτικη αντιμετωπιση του ορθοκολικου καρκινου
JP2014221779A5 (enExample)
JP2015078230A5 (enExample)
JP2014218522A5 (enExample)
CY1121910T1 (el) Φαρμακευτικο παρασκευασμα που περιεχει παραγωγο διυδροκιναζολινης με αντιϊικη δραση
UA109698C2 (xx) Похідні азаіндазолу або діазаіндазолу як медикамент
JP2014511891A5 (enExample)
WO2015025228A3 (en) Compositions and therapeutic methods for accelerated plaque regression
EA201301240A1 (ru) Полиморфная форма бензоата линаглиптина
JP2016511753A5 (enExample)
EP3412668A3 (en) A selective inhibitor of phosphatidylinositol 3-kinase-gamma
JP2016510326A5 (enExample)
MX2017002967A (es) Composicion farmaceutica novedosa que contiene derivado de acido hidroxamico o sal del mismo.
EA201490552A1 (ru) Холиновая соль замещенного циклобутендиона, обладающая противовоспалительной способностью
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
NZ605444A (en) Salt and solvates of a tetrahydroisoquinoline derivative
AR095098A1 (es) Derivado de azol benceno con actividad inhibidora de xantina oxidasa
EP2987786A4 (en) AMIDOPYRIDINOL DERIVATIVE OR PHARMACEUTICAL, SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE SUBSTANCE